Oric Pharmaceuticals, Inc. (ORIC) is a publicly traded company in the Unknown sector. Across all available filings, 15 corporate insiders have executed 158 transactions totaling $50.2M, demonstrating a bearish sentiment with -$25.5M in net insider flow. The most recent transaction on Jan 2, 2026 involved a transaction of 40,000 shares valued at $0.
No significant insider buying has been recorded for ORIC in the recent period.
No significant insider selling has been recorded for ORIC in the recent period.
Based on recent SEC filings, insider sentiment for ORIC is bearish with an Insider Alignment Score of 25/100 and a net flow of -$25.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Oric Pharmaceuticals, Inc. (ORIC) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 15 insiders are actively trading ORIC stock, having executed 158 transactions in the past 90 days. The most active insider is Carl L. Gordon (Executive), who has made 18 transactions totaling $19.7M.
Get notified when executives and directors at ORIC file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Dier Mardi | Executive | Award | 40,000 | $N/A | $0 | |
| Jan 2, 2026 | A. Heyman Richard | Executive | Award | 40,000 | $N/A | $0 | |
| Jan 2, 2026 | L. Hoerter Steven | Executive | Award | 40,000 | $N/A | $0 | |
| Jan 2, 2026 | Anne Kunkel Lori | Executive | Award | 40,000 | $N/A | $0 | |
| Jan 2, 2026 | You Angie | Executive | Award | 40,000 | $N/A | $0 | |
| Dec 16, 2025 | Chacko Jacob | Executive | Sale | 33,374 | $9.06 | $302.4K | |
| Dec 16, 2025 | Piscitelli Dominic | Executive | Sale | 10,720 | $9.06 | $97.1K | |
| Dec 16, 2025 | S. Multani Pratik | Executive | Sale | 10,720 | $9.06 | $97.1K | |
| Dec 15, 2025 | Chacko Jacob | Executive | Option Exercise | 83,666 | $N/A | $0 | |
| Dec 15, 2025 | Piscitelli Dominic | Executive | Option Exercise | 29,333 | $N/A | $0 | |
| Dec 15, 2025 | S. Multani Pratik | Executive | Option Exercise | 29,333 | $N/A | $0 | |
| Dec 8, 2025 | Anne Kunkel Lori | Executive | Option Exercise | 10,000 | $7.90 | $79.0K | |
| Dec 4, 2025 | Anne Kunkel Lori | Executive | Option Exercise | 5,534 | $3.75 | $20.8K | |
| Oct 6, 2025 | Chacko Jacob | Executive | Sale | 37,461 | $12.32 | $461.5K | |
| Oct 6, 2025 | Piscitelli Dominic | Executive | Option Exercise | 11,000 | $4.36 | $48.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 101 | $37.9M | 74.6% |
Purchase(P) | 9 | $12.3M | 24.3% |
Exercise(M) | 16 | $546.2K | 1.1% |
Award(A) | 5 | $0 | 0.0% |
Other(J) | 6 | $0 | 0.0% |
Conversion(C) | 21 | $0 | 0.0% |
Insider selling pressure at Oric Pharmaceuticals, Inc. has increased, with 15 insiders executing 158 transactions across all time. Total sales of $37.9M significantly outpace purchases of $12.3M, resulting in a net outflow of $25.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.